Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836439 | 1.00 | MAPT (0.46) | MAPTTDP1CYP11B1CYP11B2PIN1 | |
| SCHEMBL21807608 | 0.80 | MAPT (0.45) | MAPTTDP1CYP11B1CYP11B2PIN1 | |
| SCHEMBL5208631 | 0.79 | MAPT (0.50) | MAPTTDP1CYP11B1CYP11B2PIN1 | |
| SCHEMBL21836375 | 0.78 | TDP1 (0.48) | MAPTTDP1CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL21836374 | 0.78 | TDP1 (0.48) | MAPTTDP1CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL23188008 | 0.76 | CYP11B1 (0.57) | MAPTTDP1CYP11B1CYP11B2PIN1 | |
| SCHEMBL1104013 | 0.76 | ADRA1A (0.53) | MAPTTDP1CYP11B1CYP11B2PIN1 | |
| SCHEMBL1451105 | 0.75 | KDM4E (0.53) | MAPTTDP1CYP11B1CYP11B2PIN1 | |
| SCHEMBL21836362 | 0.74 | PIN1 (0.44) | MAPTTDP1PIN1ALDH1A1KDM4E | |
| SCHEMBL21807610 | 0.73 | MAPT (0.60) | MAPTTDP1ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| CN-112955142-A | Functionalized heterocyclic compounds as antiviral agents | 英安塔制药有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | MAPT 4614/4885TDP1 4189/4885CYP11B1 127/4885 |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | MAPT 4614/4885TDP1 4189/4885CYP11B1 127/4885 |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | MAPT 4614/4885TDP1 4189/4885CYP11B1 127/4885 |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | MAPT 4614/4885TDP1 4189/4885CYP11B1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.